Presentation is loading. Please wait.

Presentation is loading. Please wait.

Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Published byNathan Boyd Modified over 9 years ago

Similar presentations

Presentation on theme: "Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82."— Presentation transcript:

1 Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82 years with a history of vascular disease or with cardiovascular risk factors Randomized to pravastatin 40 mg/d or placebo Baseline TC 155–348 mg/dL Follow-up 3.2 years (mean) Primary endpoint (composite): coronary death, nonfatal MI, fatal or nonfatal stroke Shepherd J et al. Lancet 2002;360:1623–1630.

2 Slide Source: Lipids Online Slide Library www.lipidsonline.org Kaplan–Meier Analysis of Time to Primary Endpoint: PROSPER Follow-up (years) 0.51.03.501.54.0 Shepherd J et al. Lancet 2002;360:1623–1630. Reprinted with permission from Elsevier Science. Proportion with Event (%) 2.02.53.0 Number at Risk Placebo Pravastatin 2913 2891 2832 2812 2748 2738 2651 2655 2560 2562 2458 2483 2128 2167 730 770 44 40 Placebo Pravastatin p=0.014

3 Slide Source: Lipids Online Slide Library www.lipidsonline.org Major Endpoints: PROSPER Shepherd J et al. Lancet 2002;360:1623–1630. Endpoint Pravastatin (%) Placebo (%) Hazard ratio p Primary endpoint: CHD death/MI/stroke 14.116.20.850.014 Secondary endpoints: CHD death/MI 10.112.20.810.006 Fatal or nonfatal stroke 4.74.51.030.81 Other outcomes: Nonfatal MI 7.78.70.860.10 Nonfatal stroke 4.04.10.980.85 Transient ischemic attack 2.73.50.750.051 All CV events 15.718.00.850.012

4 Slide Source: Lipids Online Slide Library www.lipidsonline.org Mortality by Cause: PROSPER Cause of death Pravastatin (%) Placebo (%) Hazard ratio p CHD3.34.20.760.043 Stroke0.80.51.570.19 Vascular4.75.40.850.16 Nonvascular5.65.11.110.38 Cancer4.03.11.280.082 Trauma/suicide0.10.2NANA All causes 10.310.50.970.74 Shepherd J et al. Lancet 2002;360:1623–1630.

5 Slide Source: Lipids Online Slide Library www.lipidsonline.org First New Cancer Diagnoses by Site: PROSPER Shepherd J et al. Lancet 2002;360:1623–1630. Site Pravastatin (n) Placebo (n) Hazard ratio p Breast18111.650.19 Gastrointestinal65451.460.053 Renal or genitourinary 58591.000.99 Respiratory46421.120.60 Other58421.410.092 Total2451991.250.020

Download ppt "Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82."

Similar presentations

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
Slide Source: Lipids Online Slide Library www.lipidsonline.org Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.
Lancet 2005 366: 1267-1134 doi:10.1016/S0140-6736(08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.

Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:757-767.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.

Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:2998-3007 ALLHAT- LLT.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.

Similar presentations

Ads by Google